• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.

作者信息

Suh Cheolwon, Park Byeong-Bae, Kim Won Seog

机构信息

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Division of Hematology/Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.

出版信息

Blood Res. 2017 Mar;52(1):3-6. doi: 10.5045/br.2017.52.1.3. Epub 2017 Mar 27.

DOI:10.5045/br.2017.52.1.3
PMID:28401092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5383584/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e70d/5383584/54b8052f072f/br-52-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e70d/5383584/54b8052f072f/br-52-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e70d/5383584/54b8052f072f/br-52-3-g001.jpg

相似文献

1
The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.淋巴瘤生存改善联盟（CISL）：近期成果与未来展望
Blood Res. 2017 Mar;52(1):3-6. doi: 10.5045/br.2017.52.1.3. Epub 2017 Mar 27.
2
Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party.韩国血液学会淋巴瘤工作组淋巴瘤生存改善联盟开展的临床研究综述。
Blood Res. 2013 Sep;48(3):171-7. doi: 10.5045/br.2013.48.3.171. Epub 2013 Sep 25.
3
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.韩国淋巴瘤流行病学及真实临床领域，包括淋巴瘤生存改善联盟（CISL）试验。
Int J Hematol. 2018 Apr;107(4):395-404. doi: 10.1007/s12185-018-2403-9. Epub 2018 Jan 22.
4
Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea.淋巴瘤生存改善联盟（CISL）：韩国淋巴瘤研究的多中心合作模式。
Blood Res. 2015 Dec;50(4):187-8. doi: 10.5045/br.2015.50.4.187. Epub 2015 Dec 21.
5
Organ-specific considerations for marginal zone lymphomas in Korea, based on Consortium for Improving Survival of Lymphoma (CISL) and Korean clinical studies.基于淋巴瘤生存改善联盟（CISL）及韩国临床研究的韩国边缘区淋巴瘤的器官特异性考量
Blood Res. 2019 Mar;54(1):4-6. doi: 10.5045/br.2019.54.1.4. Epub 2019 Mar 21.
6
Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report.非霍奇金淋巴瘤患者卵巢受累的临床特征及其与预后的相关性：改善淋巴瘤生存合作组（CISL）报告。
Leuk Res. 2010 Sep;34(9):1175-9. doi: 10.1016/j.leukres.2010.02.010. Epub 2010 Mar 5.
7
Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study.韩国的眼内淋巴瘤：淋巴瘤生存改善联盟（CISL）研究
Blood Res. 2015 Dec;50(4):242-7. doi: 10.5045/br.2015.50.4.242. Epub 2015 Dec 21.
8
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.R-CVP 方案Ⅱ期研究后行利妥昔单抗维持治疗晚期边缘区淋巴瘤患者：改善淋巴瘤生存（CISL）研究联盟。
Cancer Commun (Lond). 2019 Oct 16;39(1):58. doi: 10.1186/s40880-019-0403-7.
9
Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.I/II期边缘区淋巴瘤经确定性局部治疗后进行额外化疗是否有作用？淋巴瘤生存改善联盟（CISL）研究。
Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.
10
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.利妥昔单抗联合 CVP 方案化疗治疗晚期边缘区淋巴瘤的 II 期临床试验：改善淋巴瘤生存联盟（CISL）研究。
Ann Hematol. 2012 Apr;91(4):543-51. doi: 10.1007/s00277-011-1337-6. Epub 2011 Sep 16.

引用本文的文献

1
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study.强化利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松 8 周期治疗晚期或大肿块弥漫性大 B 细胞淋巴瘤：改善淋巴瘤生存的多中心联盟（CISL）研究。
Cancer Res Treat. 2023 Oct;55(4):1355-1362. doi: 10.4143/crt.2023.271. Epub 2023 Mar 30.
2
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.韩国淋巴瘤流行病学及真实临床领域，包括淋巴瘤生存改善联盟（CISL）试验。
Int J Hematol. 2018 Apr;107(4):395-404. doi: 10.1007/s12185-018-2403-9. Epub 2018 Jan 22.

本文引用的文献

1
Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study.韩国的眼内淋巴瘤：淋巴瘤生存改善联盟（CISL）研究
Blood Res. 2015 Dec;50(4):242-7. doi: 10.5045/br.2015.50.4.242. Epub 2015 Dec 21.
2
Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.吉西他滨、地塞米松和顺铂（GDP）挽救性化疗用于复发或难治性外周T细胞淋巴瘤患者：淋巴瘤生存改善联盟（CISL）试验
Ann Hematol. 2015 Nov;94(11):1845-51. doi: 10.1007/s00277-015-2468-y. Epub 2015 Aug 8.
3
Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.
I/II期边缘区淋巴瘤经确定性局部治疗后进行额外化疗是否有作用？淋巴瘤生存改善联盟（CISL）研究。
Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.
4
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.利妥昔单抗联合Hyper-CVAD方案治疗韩国散发性伯基特或伯基特样淋巴瘤患者的疗效：一项多中心分析结果
Cancer Res Treat. 2015 Apr;47(2):173-81. doi: 10.4143/crt.2014.055. Epub 2014 Oct 28.
5
Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.接受高剂量环磷酰胺、长春新碱、阿霉素和地塞米松（hyper-CVAD）诱导治疗后行造血干细胞移植的成年淋巴细胞淋巴瘤患者治疗结果的多中心分析
Ann Hematol. 2015 Apr;94(4):617-25. doi: 10.1007/s00277-014-2258-y. Epub 2014 Dec 3.
6
Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).在老年弥漫性大B细胞淋巴瘤患者中，R-CHOP诱导化疗四个周期后进行利妥昔单抗巩固治疗：淋巴瘤生存改善联盟研究（CISL）
Eur J Haematol. 2015 Jun;94(6):504-10. doi: 10.1111/ejh.12459. Epub 2014 Nov 21.
7
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱及泼尼松化疗治疗原发性鼻窦弥漫性大B细胞淋巴瘤患者的临床结局及预后：淋巴瘤生存改善联盟的一项研究
Leuk Lymphoma. 2015 Apr;56(4):1020-6. doi: 10.3109/10428194.2014.946027. Epub 2014 Aug 20.
8
Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.同步放化疗后序贯含L-天冬酰胺酶的化疗方案VIDL用于局限性鼻型结外NK/T细胞淋巴瘤：CISL08-01 II期研究
Ann Hematol. 2014 Nov;93(11):1895-901. doi: 10.1007/s00277-014-2137-6. Epub 2014 Jun 20.
9
Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study.瓦尔代尔环非霍奇金淋巴瘤的临床特征、病理分布及预后因素：韩国全国性研究
Korean J Intern Med. 2014 May;29(3):352-60. doi: 10.3904/kjim.2014.29.3.352. Epub 2014 Apr 29.
10
Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.韩国套细胞淋巴瘤患者的临床特征与治疗结果：淋巴瘤生存改善联盟的研究
Blood Res. 2014 Mar;49(1):15-21. doi: 10.5045/br.2014.49.1.15. Epub 2014 Mar 24.